|Bid||7.02 x 1000|
|Ask||7.07 x 800|
|Day's range||7.02 - 7.41|
|52-week range||6.90 - 50.09|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||16 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||17.50|
To get a sense of who is truly in control of CureVac N.V. ( NASDAQ:CVAC ), it is important to understand the ownership...
The consensus price target hints at a 139% upside potential for CureVac N.V. (CVAC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Issuer: CureVac / Key word(s): Quarterly / Interim Statement16.11.2022 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2022 and Provides Business Update Delivering on broad second-generation vaccine development program with expansion into modified mRNA technology in collaboration with GSK Phase 1 studies in influenza and COVID-19 on track to deliver clinical data in Q1 2023 St